Literature DB >> 27134980

An Atypical and Resistant Case of Obsessive Compulsive Disorder Responding Satisfactorily with an Unusual way of Exposure and Response Prevention Therapy.

Kamal Nath1, Robin Victor2, Subrata Naskar2.   

Abstract

It is well established fact that a combination of pharmacological therapy plus cognitive behaviour therapy (CBT) - exposure and response prevention (ERP) is considered first line for the treatment of obsessive compulsive disorder (OCD). This case presented here supports this point in unusual way of ERP administration in an atypical and resistant case of OCD proved to be beneficial over pharmacotherapy. The case was atypical in the sense that it had many overvalued ideas, superstitions and religious beliefs playing major role in its aetiology. Also, misconstruction of chance associations, intense stimulus generalization and invivo exposure proving the best modality of treatment made it atypical.

Entities:  

Keywords:  Cognitive behaviour therapy; Invivo exposure; Overvalued ideas; Religious-cultural beliefs and superstitions; Treatment resistance

Year:  2016        PMID: 27134980      PMCID: PMC4843365          DOI: 10.7860/JCDR/2016/18633.7481

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

Review 1.  DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria.

Authors:  Michael Van Ameringen; Beth Patterson; William Simpson
Journal:  Depress Anxiety       Date:  2014-03-10       Impact factor: 6.505

2.  Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study.

Authors:  Nitin Anand; Paulomi M Sudhir; Suresh Bada Math; K Thennarasu; Y C Janardhan Reddy
Journal:  J Anxiety Disord       Date:  2011-06-01

3.  Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Authors:  H B Simpson; K S Gorfinkle; M R Liebowitz
Journal:  J Clin Psychiatry       Date:  1999-09       Impact factor: 4.384

4.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.

Authors:  Borwin Bandelow; Leo Sher; Robertas Bunevicius; Eric Hollander; Siegfried Kasper; Joseph Zohar; Hans-Jürgen Möller
Journal:  Int J Psychiatry Clin Pract       Date:  2012-04-30       Impact factor: 1.812

5.  [World Health Organization places psychiatry high on the agenda, also consequences for the Netherlands].

Authors:  W A Nolen
Journal:  Ned Tijdschr Geneeskd       Date:  2002-02-16

6.  Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial.

Authors:  David F Tolin; Nicholas Maltby; Gretchen J Diefenbach; Scott E Hannan; Patrick Worhunsky
Journal:  J Clin Psychiatry       Date:  2004-07       Impact factor: 4.384

Review 7.  Biological approaches to treatment-resistant obsessive compulsive disorder.

Authors:  W K Goodman; C J McDougle; L C Barr; S C Aronson; L H Price
Journal:  J Clin Psychiatry       Date:  1993-06       Impact factor: 4.384

8.  A predictive study of obsessive-compulsive disorder response to clomipramine.

Authors:  R D Alarcon; J W Libb; D Spitler
Journal:  J Clin Psychopharmacol       Date:  1993-06       Impact factor: 3.153

Review 9.  Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies.

Authors:  M A Jenike; S L Rauch
Journal:  J Clin Psychiatry       Date:  1994-03       Impact factor: 4.384

10.  Predictors of drug treatment response in obsessive-compulsive disorder.

Authors:  L Ravizza; G Barzega; S Bellino; F Bogetto; G Maina
Journal:  J Clin Psychiatry       Date:  1995-08       Impact factor: 4.384

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.